Author + information
- Jianting Yao, MD, PhDa,
- Weiwei Gao, MDa,
- Yu Wang, MD, PhDa,
- Lu Wang, PhDa,
- Kamal Diabakte, MDa,
- Jinyang Li, MDb,c,
- Jiemei Yang, MDa,
- Yongxing Jiang, MDa,
- Yuerong Liu, MDa,
- Shuyuan Guo, MDa,
- Xuezhu Zhao, MDa,
- Zhengyu Cao, MDa,
- Xi Chen, MD, PhDa,
- Qiannan Li, MDa,
- Haiyu Zhang, PhDa,
- Wei Wang, MDa,
- Zhen Tian, PhDb,c,
- Bicheng Li, MD, PhDa,
- Fang Tian, MD, PhDa,
- Guodong Wu, MDa,
- Shirin Pourteymour, PhDd,
- Xi Huang, MDa,
- Fancheng Tan, MDb,c,
- Xiaoru Cao, MDb,c,
- Zhuowen Yang, MDa,
- Kang Li, PhDe,
- Yan Zhang, PhDf,
- Yong Li, MD, PhDg,
- Zhiguo Zhang, PhDh,
- Hong Jin, MD, PhDd,∗∗ ( and )
- Ye Tian, MD, PhDa,b,c,∗ ()
- aDepartment of Cardiology, the First Affiliated Hospital, Cardiovascular Institute, Harbin Medical University, Harbin, People’s Republic of China
- bDepartment of Pathophysiology and Key Laboratory of Cardiovascular Pathophysiology, Harbin Medical University, Harbin, People’s Republic of China
- cKey Laboratory of Cardiovascular Medicine Research (Harbin Medical University), Ministry of Education, Harbin, People’s Republic of China
- dDepartment of Medicine, Karolinska Institute, Stockholm, Sweden
- eDepartment of Epidemiology and Biostatistics, Harbin Medical University, Harbin, People’s Republic of China
- fSchool of Life Science and Technology, Research Center for Computational Biology, Harbin Institute of Technology, Harbin, People’s Republic of China
- gDepartment of Positron Emission Tomography–Computed Tomography, the First Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China
- hLaboratory of Photo- and Sono-theranostic Technologies and Condensed Matter Science and Technology Institute, Harbin Institute of Technology, Harbin, People’s Republic of China
- ↵∗Address for correspondence:
Dr. Ye Tian, Department of Cardiology, The First Affiliated Hospital, Cardiovascular Institute, Harbin Medical University, 23 Youzheng Street, Harbin 150001, China.
- ↵∗∗Dr. Hong Jin, Molecular Vascular Medicine, Medicine Department, Bioclinicum, Akademiska Stråket 1, J8:20, Karolinska University Hospital, 17164 Solna, Sweden.
• DVDMS-SDT reduces neovascularization in late-stage atherosclerotic lesions in both rabbit and mouse models.
• DVDMS-SDT enhances macrophage foam cell apoptosis, which in turn induces neovessel endothelial cell apoptosis and inhibits its proliferation, migration, and tubulogenesis, termed apoptosis-induced apoptosis.
• Mechanistically, DVDMS-SDT induces macrophage foam cell apoptosis via mitochondrial-caspase pathway, which activates caspase 3 to cleave SP-1, leading to the reduction of HIF-1α and VEGF-A.
• In the pilot translational study, DVDMS-SDT reduces plaque angiogenesis and inhibits vessel inflammation.
During atherosclerosis plaque progression, pathological intraplaque angiogenesis leads to plaque rupture accompanied by thrombosis, which is probably the most important cause of arteries complications such as cerebral and myocardial infarction. Even though few treatments are available to mitigate plaque rupture, further investigation is required to develop a robust optimized therapeutic method. In this study using rabbit and mouse atherosclerotic models, sinoporphyrin sodium (DVDMS)-mediated sonodynamic therapy reduced abnormal angiogenesis and plaque rupture. Briefly, DVDMS is injected to animals, and then the plaque was locally exposed to pulse ultrasound for a few minutes. Furthermore, a small size clinical trial was conducted on patients with atherosclerosis. Notably, a significant reduction of arterial inflammation and angiogenesis was recorded following a short period of DVDMS-mediated sonodynamic therapy treatment. This beneficial outcome was almost equivalent to the therapeutic outcome after 3-month intensive statin treatment.
- apoptosis-induced apoptosis
- atherosclerotic plaque
- endothelial cell
- sonodynamic therapy
Pathological angiogenesis is a crucial factor that leads to vulnerable atherosclerotic plaque rupture (1). Thus, inhibition of plaque neovascularization provides an important therapeutic strategy to minimize or even prevent vulnerable lesion disruption and subsequent atherothrombotic complications. Vascular endothelial growth factor A (VEGF-A), a well-known hypoxia-inducible factor (HIF) target gene, constitutes the main regulator of neovascularization (2). To date, VEGF-A inhibitors have been used as systemic medications that directly exert an effect on endothelial cells to inhibit angiogenesis in cancer chemotherapy. However, the use of current VEGF-A blockers results in severe or even fatal off-target effects, such as hypertension and thromboembolism, because of the disruption of endothelial homeostasis (3–5). Therefore, a site-specific treatment that indirectly targets neovessel endothelial cells may present a safer and more feasible alternative to suppress plaque neovascularization.
Pathological neovessels induce intraplaque hemorrhage and inflammatory signals that result in the infiltration of macrophages into atherosclerotic plaques (6). In turn, these macrophages secrete VEGF-A on HIF-1α activation to promote pathological angiogenesis, vascular permeability, and inflammatory cell recruitment (7). The mutual exacerbation of pathological neovascularization and macrophage-mediated inflammation triggers plaque rupture (1,8). Accordingly, suppressing macrophage-mediated inflammation may play an essential role in inhibiting plaque neovascularization.
Sonodynamic therapy (SDT) constitutes a noninvasive treatment that utilizes ultrasound to locally activate sonosensitizer, thereby stimulating the production of reactive oxygen species to modulate cell function or fate (9). We previously demonstrated that 5-aminolevulinic acid (ALA)-mediated SDT stabilizes plaques by inducing macrophage apoptosis and clearance without causing obvious off-target effects (10). However, the beneficial effect of SDT toward plaque neovascularization has not yet been defined. Additionally, the sonosensitizer precursor ALA by oral administration needs to be converted into sonosensitizer protoporphyrin IX through metabolism, meaning high dosage in clinical practice. Sinoporphyrin sodium (DVDMS), a novel sonosensitizer, triggered mitochondrial-caspase–dependent apoptosis in human esophageal cancer (ECA-109) cells and was observed to have higher brightness and singlet oxygen-generation efficiency than protoporphyrin IX (11). Therefore, in the present study, we utilized DVDMS as a sonosensitizer in rabbit and apolipoprotein E (ApoE)−/− mouse models of advanced plaque, as well as in patients with atherosclerosis, to investigate whether sinoporphyrin sodium-mediated sonodynamic therapy (DVDMS-SDT) produces significant protective effects on lesion stabilization by suppressing neovascularization. Moreover, human leukemia monocytic cell (THP-1) and mouse peritoneal macrophage-derived foam cells, human umbilical vein endothelial cells (HUVEC), and mouse aortic endothelial cells were utilized to elucidate the underlying mechanisms.
The animal protocol was approved by the Ethics Committee of Harbin Medical University. All experiments were performed in accordance with ethical guidelines set out by the United Kingdom Animals (Scientific Procedures) Act 1986 and Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes. Studies conformed to the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health. Adult male New Zealand White rabbits (Solarbio Bioscience and Technology Co., Ltd., Shanghai, China) and male ApoE−/− mice (Vital River Laboratory Animal Technology Co., Ltd., Beijing, China) (C57BL6 background) were housed in the Animal Care Facilities of the First Affiliated Hospital of Harbin Medical University. Expanded methods are available in the Supplemental Appendix.
THP-1 cells, mouse peritoneal macrophages, primary HUVEC (Cyagen Biosciences Inc., Guangzhou, China), primary mouse aortic endothelial cells, and human embryonic kidney cells (HEK-293, catalog no. CRL-1573; ATCC, Manassas, Virginia) were cultured in a humidified atmosphere with 5% CO2 at 37°C as described in the Supplemental Appendix.
This clinical pilot study was conducted at the First Affiliated Hospital of Harbin Medical University between February 2016 and May 2017 in compliance with the principles of the Declaration of Helsinki and according to Good Clinical Practice guidelines. In the stage 1 study, of 42 subjects who were initially screened, 24 subjects received SDT treatment with complete data documented. In the stage 2 study, of 32 subjects who were initially screened, 14 subjects were allocated into either SDT group or age- and sex-matched control group; 14 had evaluable ultrasound images; and 12 had evaluable fludeoxyglucose F 18–positron emission tomography–computed tomography images at the end of the study. The study protocol was described in the Supplemental Appendix.
All quantitative data are expressed as the mean ± SD. The statistical analysis was performed using GraphPad Prism (version 6.0; GraphPad Software, La Jolla, California). A normality test (Shapiro–Wilk) was performed to determine whether the data were normally distributed. If data were normally distributed, the Student’s unpaired Student's t-test was used to determine the significant difference between 2 groups. One-way analysis of variance followed by Dunnett or Tukey post hoc testing, or 1-way or 2-way analysis of variance with repeated measures followed by Dunnett or Sidak post hoc testing were used to determine the significant difference between multiple groups. All qualitative data are expressed as frequencies (proportions); Fisher exact test was performed to analyze the qualitative data. All p < 0.05 were considered statistically significant.
DVDMS-SDT suppresses neovascularization and increases the stability of rabbit and mouse advanced atherosclerotic plaque
Therapeutic ultrasound was utilized on rabbit plaques 4 h following injection of different concentrations of DVDMS. We determined 4 mg/kg DVDMS was the optimal dosage for SDT to obtain the greatest inhibitory effect on plaque progression 1 month after treatment (Supplemental Tables 1A and 1B). Four weeks after DVDMS-SDT treatment, the normalized maximal video-intensity enhancement (MVE), as a marker for neovessel density assessed by contrast-enhanced ultrasonography, was reduced by 20% compared with baseline (Figures 1A and 1B). In addition, DVDMS-SDT substantially reduced the plaque rupture rate compared with that of the control group (10% vs. 70%) (Supplemental Table 1C). Consistent with this result, histopathological analysis showed that DVDMS-SDT markedly reduced abnormal vasa vasorum density, erythrocyte membrane content (Figures 1C to 1E), macrophages, and proliferating cell nuclear antigen-positive cells in the plaque (Supplemental Table 1D).
With the same dosage of 4 mg/kg DVDMS required for SDT to inhibit plaque progression 4 weeks after treatment (Supplemental Table 2A), DVDMS-SDT treatment remarkably suppressed the neovessel density and necrotic core size in the mouse advanced plaque (Figures 1F to 1H).
DVDMS is exclusively uptaken by lesion resident macrophages and DVDMS-SDT enhances macrophage and neovascular endothelial cell apoptosis
To clarify the cell-specific response on DVDMS-SDT, we observed that 4 h after injection, DVDMS exclusively accumulated in macrophages in rabbit advanced femoral plaque rather than in arterial smooth muscle cells and endothelial cells or in normal femoral arteries (Supplemental Figures 1A to 1I). DVDMS distribution in the advanced plaques of ApoE−/− mice was consistent with that found in rabbits (Supplemental Figures 1J to 1M). Notably, at day 3 after DVDMS-SDT, the number of apoptotic macrophages in the rabbit plaque increased approximately 5-fold (Figures 2A and 2B). The protein level of cleaved caspase 3 increased 1.7-fold, whereas that of the B-cell lymphoma–extra large transmembrane molecule decreased 60% (Figures 2Cand 2D). Consistently, mouse lesion site macrophage apoptosis (Figures 3A to 3B) and neovascular endothelial cell apoptosis (Figure 3C) were significantly increased compared with those in control mice.
Co-culture cell study reveals neovascular endothelial cell apoptosis is triggered by DVDMS-SDT–induced foam cell apoptosis
We applied in vitro study to reveal the mechanisms of suppressed neovascularization. First, with optimized parameters, we discovered significant foam cell apoptosis, as well as caspase 3 activation on DVDMS-SDT (Supplemental Figures 2A to 2D, 3A to 3D, and 4). Then with the same parameter, we incubated HUVEC with 0.2 μmol/l DVDMS for 6 h and found no significant alterations of HUVEC viability, proliferation, migration, or tubulogenesis, meaning that DVDMS-SDT does not cause dysfunction of normal vascular endothelial cells (Supplemental Figure 5).
Due to the lesion resident macrophages as dominant target cells on DVDMS-SDT, we further utilized cell coculture system to observe the macrophage-endothelial cell interaction to address the mechanisms of neovascular endothelial cell apoptosis. As expected, the intracellular fluorescence intensity of DVDMS in HUVEC was only 10% of that in THP-1–derived foam cells (Supplemental Figures 2E and 2F). Consistently, the fluorescence intensity of DVDMS in mouse peritoneal macrophage-derived foam cells after incubation with 0.7 μmol/l DVDMS for 5 h was increased by approximately 9-fold, whereas that of DVDMS in mouse aortic endothelial cells was not increased (Supplemental Figures 3E and 3F).
But interestingly, when DVDMS-SDT–treated macrophage foam cells were cocultured with vascular endothelial cells, the apoptotic rate of endothelial cells increased dramatically on foam cell apoptosis (Figure 4A, Supplemental Figure 6A), whereas proliferation (Figure 4B, Supplemental Figure 6B), migration (Figure 4C, Supplemental Figure 6C), and tubulogenesis (Figure 4D, Supplemental Figure 6D) decreased significantly.
DVDMS-SDT activates caspase 3 and subsequent HIF-1α and VEGF-A reduction in foam cells via SP-1 cleavage
In addition to triggering an apoptotic cascade, caspase 3 also plays important roles in tissue differentiation and regeneration (12). However, the regulatory role of caspase 3 in angiogenesis has not been identified. To address the molecular mechanism underlying apoptotic macrophage foam cell–induced endothelial cell apoptosis on DVDMS-SDT treatment, we performed ribonucleic acid sequencing and bioinformatics analysis and found that 720 genes were significantly altered (p = 0.032) in DVDMS-SDT–treated THP-1–derived foam cells compared with DVDMS-SDT plus caspase 3 inhibitor Ac-DEVD-CHO–treated cells. Gene ontology enrichment analysis revealed that the second most affected functional pathway was angiogenesis (Figure 5A). The heat map showed that DVDMS-SDT down-regulated a number of genes associated with angiogenesis signaling including HIF-1A, which was blocked by caspase 3–specific inhibitor Ac-DEVD-CHO (Figure 5B). Studies have well established that HIF-1α promotes VEGF-A expression (13,14). In the present study, we confirmed that DVDMS-SDT reduced both messenger ribonucleic acid and protein levels of HIF-1α and VEGF-A (Figures 5C and 5D) by activating caspase 3, which was reversed by HIF-1α overexpression (Figures 6A and 6B).
However, we found no direct regulatory effect of caspase 3 on HIF-1α. Therefore, we hypothesized that caspase 3 activation by DVDMS-SDT may cleave a transcription factor that promotes HIF-1α expression. We identified 4 proteins (androgen receptor, CTNNB1, specificity protein 1 [SP-1], and MDM2) that mediate caspase 3 and HIF-1α interactions by detecting caspase 3– and HIF-1α–related subnetworks from the Human Protein Reference Database Protein-Protein Interaction network (Figure 6C). The transcription factor SP-1 is a well-recognized substrate protein of caspase 3 (15). The chromatin immunoprecipitation (ChIP)-sequencing data of SP-1 in the ENCODE (Encyclopedia of DNA Elements) project showed a significant enrichment of SP-1 in the promoter regions of HIF1A in many human cell lines (Figure 6D). Therefore, our finding validated that SP-1 bound to the HIF1A promoter region (Figure 6E) and promoted HIF1A transcription in THP-1–derived foam cells (Figure 6F). Subsequent ChIP-quantitative polymerase chain reaction showed that the interaction of SP-1 with the HIF1A promoter diminished significantly on DVDMS-SDT treatment (Figure 6G). In addition, caspase 3 activated by DVDMS-SDT cleaved SP-1, but not androgen receptor, CTNNB1, and MDM2 (Supplemental Figure 7), leading to reduced HIF-1α expression (Figures 6H to 6M); which was reversed by SP-1 overexpression (Figures 6N to 6P).
VEGF-A abolished neovascular endothelial cell apoptosis induced by apoptotic foam cells on DVDMS-SDT
Due to the significant reduction of VEGF-A levels in DVDMS-SDT–treated macrophages, we added 5 ng/ml VEGF-A in cocultured macrophage foam cells and endothelial cells and found that DVDMS-SDT–induced endothelial cell apoptosis and DVDMS-SDT–suppressed proliferation, migration, and tubulogenesis were significantly reversed by VEGF-A incubation (Figure 7, Supplemental Figure 8).
DVDMS-SDT reduces plaque angiogenesis and arterial inflammation in patients
Our pilot clinical study consisted of 2 stages, shown in Supplemental Figures 9A and 9B, respectively. Subject demographic data and characteristics at baseline in stage 1 and stage 2 studies are shown in Supplemental Tables 3A and 3C.
In the stage 1 study, no significant difference in blood test parameters was observed after DVDMS-SDT treatment (Supplemental Table 3B). In the stage 2 study, the normalized MVE in plaque at 1 month after DVDMS-SDT was reduced by 20.4% as shown by contrast-enhanced ultrasonography analysis (Figures 8A to 8D) compared with baseline. One month after treatment, fludeoxyglucose F 18–positron emission tomography–computed tomography analysis showed that the whole vessel-target-to-background ratio (TBR) in the control group increased by 2.6% and decreased by 10% in the DVDMS-SDT group, whereas the active slice TBR decreased by 7.3% and 15% in the respective groups. In turn, the respective most-diseased segment TBR data decreased by 8% and 20% (Figures 8E to 8N).
Despite vast knowledge and efforts toward controlling neovascularization in atherosclerosis to prevent plaque rupture (16), crucial challenges remain to effectively inhibit angiogenesis without causing off-target effects. In the present study, we examined the role of DVDMS-SDT in angiogenesis inhibition, based on our previous in vivo data that ALA-SDT significantly stabilized atherosclerotic plaques and inhibited lesion development (10). Therefore, we used 2 animal models generated via different methods of inducing atherosclerotic plaque formation, to mimic endothelial dysfunction or lipid metabolism disorder–promoted atherosclerosis in humans. Notably, on DVDMS-SDT treatment with much lower dosage of sonosensitizer (0.2 mg/kg) compared with ALA (20 mg/kg) as we used in former study (10), both the rabbit and ApoE−/− mouse models manifested similar and highly consistent phenotypes with markedly decreased neovasculature, along with enhanced apoptosis of macrophages and neovascular endothelial cells in the regressed lesions.
Because DVDMS is taken up exclusively by plaque resident macrophages but not by arterial smooth muscle or endothelial cells, we proposed that the macrophage apoptosis in response to DVDMS-SDT may stimulate neovascular endothelial cell apoptosis to inhibit plaque neovascularization. Previously, Xiong et al. (17) demonstrated that the number, length, and area of capillary-like structures were significantly reduced after exposure of cultured HUVEC to DVDMS (0.05 μmol/l for 3 h) plus 90-s continuous ultrasound (2 W/cm2, 1.1 MHz). However, we found that DVDMS (0.2 μmol/l for 6 h) plus 5-min pulse ultrasound (0.7 W/cm2, 1 MHz, duty cycle: 10%) had no direct effect on HUVEC viability, which further strengthened the study rationale that applied DVDMS-SDT protocol in the present study results in a minimal damage to normal arterial endothelial cells with significant enhancement in plaque stability.
Based on the established close spatiotemporal association between tissue macrophages and sprouting vessels (18), we used a coculture system of macrophages and vascular endothelial cells to mimic the plaque microenvironment. Consequently, we report the novel observation that macrophage foam cell apoptosis in response to DVDMS-SDT markedly promoted endothelial cell apoptosis through a reduction in VEGF-A levels. Interestingly, Winnik et al. (19) reported that systemic VEGF inhibition exacerbated atherosclerosis in ApoE−/− mice on high fat diet, which is different from our results. We consider the phenotype difference is due to different vascular biofunction and pathological reaction on systemic or local impact of VEGF-A.
Next, we attempted to address the molecular signaling pathway in macrophages following DVDMS-SDT to reveal the underlying mechanisms for subsequent endothelial apoptosis through ribonucleic acid sequencing and bioinformatics analyses on DVDMS-SDT–treated foam cells with or without apoptosis inhibition. We found that angiogenesis represented the second most responsive signaling pathway, with HIF-1α identified being involved in this process. HIF-1α constitutes a key transcription factor regulating hypoxia responses including cell apoptosis in atherosclerotic plaque; notably, it is also expressed in macrophages regulating their function (20).
Moreover, we found that DVDMS-SDT–activated caspase 3 cleaves SP-1 to inhibit the expression of HIF-1α, as well as VEGF-A reduction in macrophage foam cells, which is consistent with the results of other studies that activated caspase 3 by different apoptotic inducers, cleaving SP-1 on the aspartic acid 183 or 584 site (21,22). VEGF-A plays an important role in maintaining endothelial cell viability by binding to its receptor VEGFR2 (3). Hence, VEGF-A reduction may induce neovascular endothelial cell apoptosis (23). Although HIF-1α is known to bind to the promoter of caspase 3 to regulate its expression (24), the means by which caspase 3 inhibits HIF-1α expression requires further investigation. Our results revealed hypoxia–HIF-1α–caspase 3–SP-1–HIF-1α as a novel feedback signaling pathway, although the specific caspase 3 site of action on SP-1 is not known yet. It is therefore necessary to further analyze the cluster of genes and other metabolic pathways in our ribonucleic acid sequencing database to achieve a more comprehensive understanding of the role of DVDMS-SDT in atherosclerotic plaque stability.
Based on the promising findings from our in vivo and in vitro studies, we also conducted a small size pilot study in patients with atherosclerosis. Notably, a significant reduction of neovascularization and arterial inflammation was recorded following a short period of DVDMS-SDT treatment. This beneficial effect was almost equivalent to the therapeutic outcome after 3-month intensive statin treatment (25) but occurred earlier than the statin-mediated effect. Moreover, our regular follow-up screening shows no side effects consequent to DVDMS-SDT administration to date. The findings of the present study therefore suggest that DVDMS-SDT alone or in combination with a reduced statin dosage may potentially produce lesion-specific therapeutic effects in patients with vulnerable atherosclerotic plaques.
The present small-scale pilot study was neither randomized nor double-blinded. We are currently in the process of assessing the safety and efficacy profile of DVDMS-SDT on atherosclerotic plaques in larger randomized, double-blinded, controlled trials; the results of these trials will be reported in due course (SMART-PAD [Sonodynamic Therapy Manipulates Atherosclerosis Regression Trial on Patients With PAD and Claudication], NCT03457662; SMART-C [Sonodynamic Therapy Manipulates Atherosclerosis Regression Trial on Patients With Carotid Atherosclerotic Plaques], NCT03382249).
As shown in Figure 9, DVDMS-SDT successfully inhibits atherosclerotic plaque neovascularization by promoting macrophage apoptosis-induced endothelial cell apoptosis. Although this noninvasive treatment undoubtedly requires further development and refinement, it represents a promising clinical strategy to prevent vulnerable plaque from intraplaque hemorrhage or thrombotic complications.
COMPETENCY IN MEDICAL KNOWLEDGE: Systemic VEGF-A inhibitors are widely used to inhibit tumor angiogenesis but are not therapeutically viable in patients with chronic atherosclerosis because long-term inhibition is associated with severe or even fatal cardiovascular side effects. DVDMS-SDT locally inhibits atherosclerotic plaque neovascularization via macrophage apoptosis-induced endothelial cell apoptosis without any obvious off-target effects and has potential therapeutic value.
TRANSLATIONAL OUTLOOK: Randomized controlled trials are needed to establish the safety and efficacy of DVDMS-SDT toward atherosclerotic plaque neovascularization.
This work was funded by the State Key Program of the Natural Science Foundation of China (81530052 to Dr. Tian), the major scientific instrument equipment development project of China (81727809 to Dr. Y. Tian), and the Magnus Bergvalls Stiftelse Foundation of Sweden (2018-02582 to Dr. Jin). The authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Yao and Gao contributed equally to this work and are joint first authors.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Basic to Translational Science author instructions page.
- Abbreviations and Acronyms
- 5-aminolevulinic acid
- apolipoprotein E
- chromatin immunoprecipitation
- sinoporphyrin sodium
- sinoporphyrin sodium-mediated sonodynamic therapy
- hypoxia inducible factor-1α
- human umbilical vein endothelial cells
- normalized maximal video-intensity enhancement
- sonodynamic therapy
- specificity protein 1
- target-to-background ratio
- vascular endothelial growth factor A
- Received July 29, 2019.
- Revision received October 7, 2019.
- Accepted October 7, 2019.
- 2019 The Authors
- Ahmadi A.,
- Leipsic J.,
- Blankstein R.,
- et al.
- Moulton K.S.,
- Vakili K.,
- Zurakowski D.,
- et al.
- Qian X.,
- Zheng Y.,
- Chen Y.
- Sun X.,
- Guo S.,
- Yao J.,
- et al.
- Wang H.,
- Wang X.,
- Zhang S.,
- Wang P.,
- Zhang K.,
- Liu Q.
- Thirusangu P.,
- Vigneshwaran V.,
- Prashanth T.,
- et al.
- Kolodgie F.D.,
- Narula J.,
- Yuan C.,
- Burke A.P.,
- Finn A.V.,
- Virmani R.
- Xiong W.,
- Wang P.,
- Hu J.,
- et al.
- Fantin A.,
- Vieira J.M.,
- Gestri G.,
- et al.
- Aarup A.,
- Pedersen T.X.,
- Junker N.,
- et al.
- Torabi B.,
- Flashner S.,
- Beishline K.,
- et al.
- Tawakol A.,
- Fayad Z.A.,
- Mogg R.,
- et al.